Biotechnology sector-related ETFs took a blow Thursday after drugmaker Biogen (NasdaqGS: BIIB) and Eisai Co. revealed they are ending two late-stage trials for experimental Alzheimer’s therapy. The iShares Nasdaq Biotechnology ETF (NASDAQGM: IBB), the largest biotech exchange traded fund by...